The Prime Minister has today announced that the parliamentary vote on Brexit has been delayed. In response, the ABPI has emphasised the need to avoid a 'no-deal' situation.
The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a consultation on how its legislation and regulatory processes would have to be modified in the event of the UK not securing a deal with the EU after the UK’s exit, with no Implementation Period.
The MHRA has published technical guidance on what a Brexit implementation period means for the life sciences sector, once finalised as part of the Withdrawal Agreement.
Yesterday, the European Medicines Agency (EMA) announced that it will further temporarily scale back and suspend activities in preparation for Brexit. The EMA said that it expects a staff loss of about 30%.
The European Commission have published proposals for how it will allocate its budget for science spending in the next EU budget. The funding programme - Horizon Europe - is the successor to Horizon 2020 and covers the period 2021-2027.
A survey into Brexit planning by pharmaceutical companies has been published by the European Medicines Agency (EMA).
Simon Stevens appeared on the Andrew Marr Show on Sunday 1 July and was asked about preparations for Brexit and contingency planning for a no-deal scenario to ensure the continued supply of medicines to the UK.
The Department of Health and Social Care has committed £30 million to fight global AMR, delivered through 4 new projects as part of the Global AMR Innovation Fund (GAMRIF).
In a speech today, the Prime Minister Theresa May will set out plans for artificial intelligence (AI) to help to prevent 22,000 cancer deaths each year by 2033.
A report published by the Business, Energy and Indsutrial Strategy (BEIS) Strategy Committee, calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry.